research use only
Cat.No.S8759
| Related Targets | Caspase PD-1/PD-L1 Ferroptosis p53 Apoptosis related Synthetic Lethality STAT TNF-alpha Ras KRas |
|---|---|
| Other Bcl-2 Inhibitors | ABT-737 Navitoclax (ABT-263) S63845 Obatoclax Mesylate (GX15-070) A-1210477 TW-37 A-1331852 A-1155463 Dihydrochloride UMI-77 AZD5991 |
|
In vitro |
DMSO
: 100 mg/mL
(140.68 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 710.82 | Formula | C43H42N4O6 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 1448584-12-0 | -- | Storage of Stock Solutions |
|
|
| Synonyms | S 055746,BCL201 | Smiles | C1CCN2C(=C(C=C2C3=CC4=C(C=C3C(=O)N5CC6=CC=CC=C6CC5CN7CCOCC7)OCO4)C(=O)N(C8=CC=CC=C8)C9=CC=C(C=C9)O)C1 | ||
| Targets/IC50/Ki |
Bcl-2
(Cell-free assay) 1.3 nM(Ki)
|
|---|---|
| In vitro |
S55746 occupies the hydrophobic groove of BCL-2. In a panel of hematological cell lines, this compound induces hallmarks of apoptosis including externalization of phosphatidylserine, caspase-3 activation and PARP cleavage. It potently induces RS4;11 cell killing after 72 h of treatment with an IC50 of 71.6 nM and exhibits a much weaker activity in H146 (IC50 = 1.7 μM), a BCL-XL-dependent cell line, which expresses a low level of BCL-2 and high level of BCL-XL. It has no cytotoxic activity on BCL-XL-dependent cells, such as platelets. |
| In vivo |
S55746 administered by oral route daily in mice demonstrates robust anti-tumor efficacy in two hematological xenograft models (RS4;11 and Toledo models) with no weight lost and no change in behavior. |
References |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02603445 | Completed | Follicular Lymphoma Mantle Cell Lymphoma |
Novartis Pharmaceuticals|Novartis |
November 16 2015 | Phase 1 |
| NCT02920541 | Completed | Acute Myeloid Leukaemia (AML)|Myelodysplastic Syndrome (MDS) |
Institut de Recherches Internationales Servier|ADIR a Servier Group company|Servier |
January 2015 | Phase 1 |
| NCT02920697 | Completed | Chronic Lymphocytic Leukaemia (CLL)|B-Cell Non-Hodgkin Lymphoma (NHL)|Multiple Myeloma (MM) |
Institut de Recherches Internationales Servier|ADIR a Servier Group company|Servier |
March 2014 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.